Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 55
Locations 51 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dulaglutide — Administered SC

Primary Outcomes

  • Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration (Baseline through Week 26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-10
Completion: 2027-12
Eligibility
Age: 10 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
520-626-3197
University of Arizona
Interventions
  • Drug: Dulaglutide — Administered SC
Study Locations (51 sites)
University of Arizona, Tucson, Arizona 85724 United States
Arkansas Childrens Hospital, Little Rock, Arkansas 72202-3500 United States
Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California 90027 United States
UCLA Mattel Children's Hospital, Los Angeles, California 90095 United States
University of California, San Francisco, San Francisco, California 94158 United States
Children's Hospital of Colorado, Denver, Colorado 80045 United States
Yale Diabetes Research, New Haven, Connecticut 06511 United States
Emerson Clinical Research Institute, Washington D.C., District of Columbia 20009 United States
Children's National Medical Center, Washington D.C., District of Columbia 20010 United States
Nemours Children's Health, Jacksonville, Florida 32207 United States
Eligibility Criteria
Inclusion Criteria: * Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening. * Have a body weight ≥50 kilograms (kg) and Body Mass Index (BMI) of \>85th percentile Exclusion Criteria: * Have Type 1 diabetes * Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or dulaglutide within 8 weeks prior to screening * After the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome * Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness within the last 6 months * Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) * Have prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease * Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening
Conditions Healthy Volunteers, Diabetes Mellitus, T...
Phase PHASE1
Enrollment 58
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study is testing a new medicine that might help treat people with type 2 diabetes. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of participants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC1679-0001) or placebo (a treatment that has no active medicine in it). NNC1679-0001 is a new experimental medicine that doctors cannot prescribe yet. Which treatment the participant gets is decided by chance. Participant will get one dose which will be injected into the area around abdomen (belly) by the medical staff.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: NNC1679-0001 — NNC1679-0001 will be administered subcutaneously.
  • Drug: Placebo — Placebo will be administered subcutaneously.

Primary Outcomes

  • Number of Treatment-Emergency Adverse Events (TEAEs) (From dosing (day 1) upto week 34)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-05-04
Completion: 2028-06-25
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novo Nordisk A/S
Principal Investigators:
  • Clinical Transparency dept. 2834 (STUDY_DIRECTOR) - Novo Nordisk A/S
Contact Information
Study Contact:
Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com
Interventions
  • Drug: NNC1679-0001 — NNC1679-0001 will be administered subcutaneously.
  • Drug: Placebo — Placebo will be administered subcutaneously.
Study Locations (1 sites)
Medical University of Graz, Graz, 8010 Austria
Eligibility Criteria
Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male or female (sex at birth) of nonchildbearing potential. * Age 18-64 years (both inclusive) at the time of signing the informed consent. Healthy participants * Body mass index (BMI) 18.5-29.9 kilograms per square meter (kg/m\^2) (both inclusive) at screening. * Glycated haemoglobin (HbA1c) lesser than or equal to (\<=) 6.4 percent (%) (47 \[millimoles per mole\] mmol/mol) at screening. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiograms (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Participants with Type 2 Diabetes Mellitus (T2DM) * BMI 20.0-34.9 kg/m\^2 (both inclusive) at screening. * HbA1c 6.5-9.0% (47.5-74.9 mmol/mol) at screening. * Diagnosed with T2DM greater than or equal to (\>=)180 days before screening. * Stable (as judged by the investigator) daily dose(s) of metformin or combination of metformin and dipeptidyl peptidase IV (DPP-4) inhibitors and/or sodium-glucose co-transport 2 SGLT 2) inhibitors \>= 90 days before screening. Exclusion Criteria: All participants * Screening alanine aminotransferase (ALT) values greater than (\>) upper limit of normal (ULN) +10%, aspartate aminotransferase (AST) values \>ULN +20%, or total bilirubin \>ULN. * Renal impairment, defined as estimated glomerular filtration rate (eGFR) \<60.0 milliliter per minute per 1.73 square meter (mL/min/1.73m\^2), at screening. * Clinical evidence of chronic kidney disease (CKD) and/or urinary albumin: creatinine ratio (UACR) \>30 milligrams per gram (mg/g). * Presence or history of cardiovascular disease, including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders. Healthy participants * Any disorder that, in the investigator's opinion, might jeopardise participants' safety or compliance with the protocol. * Supine blood pressure at screening outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic. Participants with T2DM * Any disorder except for mild conditions under stable treatment associated with T2DM, which in the investigator's opinion might jeopardise participant safety or compliance with the protocol. * Supine blood pressure at screening outside the range of 90-159 mmHg for systolic or 50-99 mmHg for diastolic. This exclusion criterion also pertains to those participants who are receiving antihypertensive treatment.
Conditions Life Style
Phase NA
Enrollment 62
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to test the efficacy, feasibility, and safety of a bicycle exercise followed by an intensive lifestyle intervention for 3 months in patients with recent onset and medically untreated type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Lifestyle Intervention — Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling

Primary Outcomes

  • metabolic control (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-02-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Collaborators: Kantonsspital Olten
Principal Investigators:
  • Marc Y Donath, Prof. (PRINCIPAL_INVESTIGATOR) - University Hospital, Basel, Switzerland
Contact Information
Study Contact:
Marc Y Donath, Prof.
0041 61 265 50 78
marc.donath@usb.ch
Matthias Hepprich, MD
0041 61 328 60 77
matthias.hepprich@usb.ch
Marc Y Donath, Prof.
0041 61 265 50 78
marc.donath@usb.ch
University of Basel
Interventions
  • Behavioral: Lifestyle Intervention — Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
Study Locations (3 sites)
University of Basel, Basel, Canton of Basel-City 4031 Switzerland
Cantonal Hospital Olten, Olten, Canton of Solothurn 4600 Switzerland
Hopital du Jura, Delémont, 2800 Switzerland
Eligibility Criteria
Inclusion Criteria: * Informed consent as documented by signature * Type 2 diabetes diagnosed within the last two years according to the American Diabetes Association (ADA) criteria * Age ≥ 18 years * HbA1c ≥ 7.5 % Exclusion Criteria: * Clinically instable patient as defined by the physicians on duty including signs of new cardiac ischemia in the ECG, systolic blood pressure ≥ 200 mmHg, fever ≥ 38.5 °C, symptoms of SIRS or reduced vigilance. * Anti-diabetic medication for ≥ 24 hours * Inability to perform a bicycle exercise during 30 minutes * Previous lifestyle-intervention by an endocrinologist * Engagement in physical activity more than five times per week * Enrollment in other interventional study
Conditions Type 2 Diabetes
Phase NA
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to compare 2 primary care based telehealth interventions- 1) digital health coaching and 2) remote patient monitoring for improving glycemic (blood sugar levels) control and overall health outcomes in individuals with physical disabilities, type 2 diabetes (T2DM) and at least one chronic condition. The project aims to determine which intervention is more effective in reducing blood sugar levels, improving patient-reported outcomes such as diabetes-related distress, and facilitating the implementation of these approaches in real-world primary care settings serving vulnerable populations. The findings intend to inform about optimal telehealth strategies for managing multiple chronic conditions in underserved groups, there by supporting improved health equity and quality of care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Digital Health Coaching — This program will be developed using existing, evidence-based curricula for chronic disease self-management. Prior to initiating health coaching with participants, coaches will review data collected related to SDoH to further tailor the intervention as appropriate for housing stability, access to food and transportation, and interpersonal safety. All coaches will have access to participants' EMRs such that they can view medical information throughout the intervention. Coaches will be trained using a curriculum developed by Family and Community Medicine's inter-professional care team and our partners at NCHPAD, making the coaching inclusive of people with physical disabilities, such that the coaches are proficient in motivating behavior change related to resilience, physical activity, nutrition, mindfulness, and relationship-building, among others.
  • Behavioral: Continuous Glucose Monitoring Teleconsults — This comparator arm consists of continuous glucose monitoring (CGM) with periodic teleconsult visits over 6 months, delivered by trained pharmacists, RDs, or nurses, with devices shipped centrally to participants' homes. Sensors are replaced per manufacturer guidelines. During onboarding, participants receive device education and standardized safety counseling on recognizing and managing hypoglycemia (\<70 mg/dL; severe \<54 mg/dL) and hyperglycemia (\>300 mg/dL), including when to seek urgent or emergency care. During each teleconsult, the CGM team reviews Time in Range, Time Above Range, and Time Below Range, identifies patterns between glucose and lifestyle factors, and supports goal setting and medication adjustments as needed. Participants with repeated missed readings are contacted by the study team to troubleshoot adherence barriers.

Primary Outcomes

  • Change in Hemoglobin A1c (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-13
Completion: 2028-01-31
Eligibility
Age: 18 Years – 89 Years
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Tapan Mehta, PhD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Aseel El Zein, PhD
205-201-1507
assilelzein@uabmc.edu
Rebecca Rogers, MS
(205) 975-5221
rrrogers@uab.edu
Aseel El Zein Research Scientist, PhD, RDN
2052011507
assil.elzein352@gmail.com
UAB Highlands Hospital/Department of Family and Community Medicine
Interventions
  • Behavioral: Digital Health Coaching — This program will be developed using existing, evidence-based curricula for chronic disease self-management. Prior to initiating health coaching with participants, coaches will review data collected related to SDoH to further tailor the intervention as appropriate for housing stability, access to food and transportation, and interpersonal safety. All coaches will have access to participants' EMRs such that they can view medical information throughout the intervention. Coaches will be trained using a curriculum developed by Family and Community Medicine's inter-professional care team and our partners at NCHPAD, making the coaching inclusive of people with physical disabilities, such that the coaches are proficient in motivating behavior change related to resilience, physical activity, nutrition, mindfulness, and relationship-building, among others.
  • Behavioral: Continuous Glucose Monitoring Teleconsults — This comparator arm consists of continuous glucose monitoring (CGM) with periodic teleconsult visits over 6 months, delivered by trained pharmacists, RDs, or nurses, with devices shipped centrally to participants' homes. Sensors are replaced per manufacturer guidelines. During onboarding, participants receive device education and standardized safety counseling on recognizing and managing hypoglycemia (\<70 mg/dL; severe \<54 mg/dL) and hyperglycemia (\>300 mg/dL), including when to seek urgent or emergency care. During each teleconsult, the CGM team reviews Time in Range, Time Above Range, and Time Below Range, identifies patterns between glucose and lifestyle factors, and supports goal setting and medication adjustments as needed. Participants with repeated missed readings are contacted by the study team to troubleshoot adherence barriers.
Study Locations (1 sites)
UAB Highlands Hospital/Department of Family and Community Medicine, Birmingham, Alabama 35223 United States
Eligibility Criteria
Inclusion Criteria: 1. Physical Disability 2. Diagnosed with Type 2 Diabetes 3. Hemoglobin A1c ≥7% within 3 months of screening 4. Must have at least 1 additional chronic conditions from the list below Hypertension Congestive Heart Failure Coronary Artery Disease Hyperlipidemia Stroke Arthritis Asthma Cancer Chronic Kidney Disease (Stages 1-4) COPD Osteoporosis Multiple Sclerosis Parkinsons Exclusion Criteria: 1. Intellectual, Learning, Developmental Disabilities 2. Non-english speakers 3. Currently pregnant 4. Significant vision loss preventing use of phone/tablet for interventions 5. Received Remote Patient Monitoring or Digital Health Coaching for T2DM management within 30 days of enrollment 6. End-stage kidney disease (on dialysis) 7. Does not report having a physical disability 8. Perceived unwillingness or inability to participate
Conditions Diabetes Type 2
Phase PHASE4
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2 diabetes. As the primary outcome, the investigators selected the change in skeletal muscle oxidative capacity and posed the following scientific question: Does empagliflozin significantly improve the oxidative capacity of skeletal muscle? The study will enroll 54 individuals with type 2 diabetes in a prospective, randomized, interventional, open-label study. Participants will be randomized into 3 equally sized groups: 1) a group receiving empagliflozin; 2) a group receiving metformin; and 3) a group receiving a combination of both drugs (empagliflozin and metformin). The investigators will analyze the clinical variables of the subjects, near-infrared spectroscopy (NIRS) measurements over the flexor digitorum superficialis muscle of the non-dominant arm at rest, after submaximal muscular work, and during transient brachial artery occlusion at specified time intervals (14 days, 1 month, 3 months, 6 months), as well as body composition, physical performance, and glycemic control following the pharmacological intervention.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Empagliflozin (Jardiance®) — Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor administered orally at a standard therapeutic dose for the treatment of type 2 diabetes mellitus. In this study, empagliflozin will be administered alone (Arm 1) or in combination with metformin (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.
  • Drug: Metformin — Metformin is a biguanide antihyperglycemic agent administered orally at a standard therapeutic dose for the treatment of type 2 diabetes mellitus. In this study, metformin will be administered alone (Arm 2) or in combination with empagliflozin (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.
  • Combination Product: Synjardy® 12.5mg/1000mg film-coated tablets — Fixed-dose combination product containing empagliflozin and metformin, administered orally at standard therapeutic doses for the treatment of type 2 diabetes mellitus. Used in the combination therapy arm (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.

Primary Outcomes

  • Change in skeletal muscle mitochondrial oxidative capacity (Baseline, Day 14, Month 1, Month 3, and Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-04-16
Completion: 2028-07-31
Eligibility
Age: 18 Years – 75 Years
Sex: MALE
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Centre Ljubljana
Collaborators: University of Ljubljana, Faculty of Medicine
Contact Information
Study Contact:
Eva Podbregar Kolar, MD
+38640762768
evapodbregar@gmail.com
Eva Podbregar Kolar, MD
+38640762768
evapodbregar@gmail.com
UMC Ljubljana
Mojca Lunder, MD PhD
mojca.lunder@kclj.si
UMC Ljubljana
Interventions
  • Drug: Empagliflozin (Jardiance®) — Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor administered orally at a standard therapeutic dose for the treatment of type 2 diabetes mellitus. In this study, empagliflozin will be administered alone (Arm 1) or in combination with metformin (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.
  • Drug: Metformin — Metformin is a biguanide antihyperglycemic agent administered orally at a standard therapeutic dose for the treatment of type 2 diabetes mellitus. In this study, metformin will be administered alone (Arm 2) or in combination with empagliflozin (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.
  • Combination Product: Synjardy® 12.5mg/1000mg film-coated tablets — Fixed-dose combination product containing empagliflozin and metformin, administered orally at standard therapeutic doses for the treatment of type 2 diabetes mellitus. Used in the combination therapy arm (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.
Study Locations (1 sites)
UMC Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Male sex * Age 18-75 years * Newly diagnosed type 2 diabetes mellitus, confirmed no more than 2 years prior to enrollment * Body mass index (BMI) 25-35 kg/m² * Currently managed at a diabetes outpatient clinic * No known chronic diabetes-related complications * No prior antidiabetic pharmacological treatment, with the exception of sulfonylureas Exclusion Criteria: * Other forms of diabetes mellitus (i.e., not type 2) * Type 2 diabetes mellitus known for more than 2 years * Comorbidities known to independently affect skeletal muscle oxidative capacity, including: spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cystic fibrosis, local joint immobility, or hemiplegia * Known mitochondrial disease * Heart failure, NYHA class II or higher * Chronic kidney disease, stage 3 or higher * Poorly controlled chronic medical conditions (e.g., arterial hypertension, hypothyroidism) * Recurrent urinary tract infections * Active malignancy currently undergoing oncologic treatment * Life expectancy less than 3 months * Symptomatic hyperglycemia with fasting plasma glucose above 18 mmol/L, HbA1c ≥ 10% * Unwillingness to provide informed consent
Conditions Type 2 Diabets Mellitus, Cognitive Abili...
Phase PHASE3
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Cilostazol / Ginko Leaf Dried Ext. — Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
  • Drug: Placebo — Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.

Primary Outcomes

  • Change in Mini-Mental State Examination (MMSE) Score From Baseline to 6 Months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-01
Completion: 2027-06-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Bundang Hospital
Collaborators: SK Chemicals Co., Ltd.
Contact Information
Study Contact:
Soo Lim Dr., MD PhD
+82-31-787-7035
limsoo@snu.ac.kr
Minji Sohn Dr, PhD
rainbowmjs@naver.com
Interventions
  • Drug: Cilostazol / Ginko Leaf Dried Ext. — Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
  • Drug: Placebo — Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
Study Locations (1 sites)
Seoul National University Bundang Hospital, Seongnam-si, South Korea
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with type 2 diabetes mellitus * Adults aged 60 years or older * Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months Exclusion Criteria: * Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma * Patients with poorly controlled blood glucose (HbA1c \> 10.0%) * Patients with an MMSE score below 24 * Patients diagnosed with dementia (e.g., Alzheimer's disease) * Patients with suspected cognitive impairment due to other causes * Patients requiring antiplatelet or anticoagulant therapy other than the investigational product * Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels) * Patients with severe depression * Patients with severe infections, recent surgery (perioperative status), or major trauma * Patients with pituitary or adrenal insufficiency * Patients with other medical conditions requiring hospitalization * Patients with a history of alcohol or drug abuse within 1 year prior to screening * Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening * Patients deemed by the investigator to be otherwise unsuitable for study participation
Conditions Type 2 Diabetes Mellitus (T2DM) and Chro...
Phase PHASE1
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Biological: REGEND003 — REGEND003
  • Other: Placebo — Placebo

Primary Outcomes

  • Adverse Event (AE) associated with the Cell Therapy (Within 24 weeks post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-01-08
Completion: 2027-12
Eligibility
Age: 30 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regend Therapeutics
Collaborators: Shanghai Tongji Hospital, Tongji University School of Medicine
Contact Information
Study Contact:
Prof. Yu
086-021-66111062
yuchen@tongji.edu.cn
Prof. Yu
086-021-66111062
yuchen@tongji.edu.cn
Shanghai Tongji Hospital
Interventions
  • Biological: REGEND003 — REGEND003
  • Other: Placebo — Placebo
Study Locations (1 sites)
Shanghai Tongji Hospital, Shanghai, 200000 China
Eligibility Criteria
Inclusion Criteria: * Male or female, aged 30 to 75 years at the time of signing the informed consent form; * Diagnosed with Type 2 Diabetes Mellitus for at least 1 year; * Diagnosed with Chronic Kidney Disease (CKD); * Voluntarily sign the informed consent form, be able to cooperate in completing study-related procedures and examinations, capable of adequately recording or describing changes in their condition, and demonstrate strong compliance. Exclusion Criteria: * Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant); * At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test. Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well. * Presence of a current or prior history of malignant tumor at screening (with the exception of those with disease-free survival for more than 2 years, or malignancies deemed to be of low aggressiveness as assessed by the investigator). * Patients with Type 1 Diabetes Mellitus; * Patients undergoing regular hemodialysis or peritoneal dialysis; * Presence of severe acute complications of diabetes or CKD requiring hospitalization within 2 weeks prior to screening; * Presence of more than one episode of hypoglycemic coma (blood glucose ≤3.9 mmol/L) within 1 month prior to screening; * Patients intolerant to renal puncture/intrarenal injection procedures; * Patients with diagnosis of acute kidney injury, congenital or hereditary kidney diseases, renal atrophy, or other renal conditions deemed ineligible by the investigator, as well as patients with a history of kidney transplantation at screening; * Presence of severe systemic diseases within 6 months prior to screening and judged by the investigator as unsuitable for the study; * Patients requiring long-term anticoagulant or antiplatelet therapy who, in the investigator's judgment, cannot discontinue medication 1 week prior to renal puncture/intrarenal injection procedures; * Patients with suicidal risk, history of psychiatric disorders, or history of epilepsy at screening; * Patients with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening; * Patients participated in other clinical trials with interventions within 1 month prior to screening; * Subject with assessed survival time of less than 1 year by investigators at screening; * Investigators, co-investigators, study coordinators, employees of participating investigators or research centers, or family members of the above individuals; * Any condition that, in the investigator's judgment, may increase subject risk or interfere with the clinical trial.
Conditions Metabolic Diseases, Type 2 Diabetes, Car...
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

High-glycaemic foods contribute to elevated risk of obesity, type 2 diabetes, and cardiometabolic disease. Replacing digestible carbohydrates with dietary fibres is known to reduce postprandial glycaemic excursions, enhance satiety, and support beneficial microbial fermentation. However, limited evidence exists on how interactions between different isolated fibres within a processed food matrix may modulate these responses, particularly when such interactions could recreate structural features of intrinsic plant fibre networks that naturally restrict starch accessibility and alter fermentation dynamics. This randomized, single-blinded, placebo-controlled crossover trial will investigate how isolated dietary fibres, alone and in combination, influence metabolic and microbial responses when incorporated into a commonly consumed cereal-based food (scone). Overweight but otherwise healthy adults (BMI 25-\<30 kg/m²) will consume seven fibre-enriched scone formulations across two consecutive mornings per intervention phase. Outcomes include postprandial glycaemic response measured via continuous glucose monitoring (primary outcome), perceived satiety and energy intake, gastrointestinal symptoms, fermentation dynamics via breath hydrogen and methane, and gut microbiota composition assessed through 16S rRNA sequencing. This study will generate novel insights into potential synergistic interactions between isolated fibres within a food matrix and their consequences for glycaemic control, satiety, microbial fermentation, and community. Findings will inform next-generation food design strategies aimed at replicating complex intrinsic fibre structures to enhance the health impact of processed foods.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Other: Cereal-based food, Fiber-enriched scones — Scone supplemented with 4 to 20 grams of fibres, nicknamed (A, B, C, D, E, F, G)

Primary Outcomes

  • Impact on Postprandial Glycaemic Response (Measured continuously over each 2-day intervention phase, with readings recorded every 15 minutes, covering all seven scone interventions plus baseline across the 28-day study period.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-18
Completion: 2026-05
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University College Cork
Principal Investigators:
  • Jens Walter, PhD (PRINCIPAL_INVESTIGATOR) - University College Cork; University of Alberta
Contact Information
Study Contact:
Manon Oliero, PhD
+353 (0)86 199 2919
sconestudy@ucc.ie
Manon Oliero, PhD
+353 (0)86 199 2919
sconestudy@ucc.ie
University College Cork
Interventions
  • Other: Cereal-based food, Fiber-enriched scones — Scone supplemented with 4 to 20 grams of fibres, nicknamed (A, B, C, D, E, F, G)
Study Locations (1 sites)
University College Cork, Cork, Ireland
Eligibility Criteria
Inclusion Criteria: * Be willing and able to give written informed consent. * Be between 18 and 45 years of age. * Have a BMI of =25\<30kg/m2(overweight). * Have a waist circumference of \>94cm for a male, \>80cm for a female (increased risk of metabolic syndrome). * Have had a stable body weight (\<5% change over the past three months). * Be in general good health as determined by the investigator through interview and vital signs (blood pressure, pulse, temperature). Systolic blood pressure less than 160mm Hg and diastolic blood pressure less than 100 mm Hg (defined as Hypertension stage 2). * Be willing to avoid consuming dietary supplements (at the discretion of the investigator), prebiotics, probiotics, or fibre-rich supplements within four weeks before the baseline visit, and until the end of the study. * Be willing to avoid vigorous physical activities on the interventional days (defined as any physical activity that is planned to achieve a fitness goal). * Be willing to consume the investigational food products and menu plan daily for the duration of the study. Exclusion Criteria: * Pregnant, lactating, or post-menopausal women, or women who are planning to become pregnant over the study period. * Have had antibiotic treatment within three months before baseline. * Are taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of study results; to include anti-inflammatory drugs, H2 blockers, antacids, proton pump inhibitors, anti-hypertensive medications, corticosteroids, laxatives, enemas, antibiotics, anti-coagulants, and immunosuppressant medication. Participants should have a wash-out period of at least two weeks for each of these medications except for antibiotics, which should not have been taken in the previous three months. Participants taking proton pump inhibitors and medications for chronic conditions (e.g., anti-hypertensive medication) will be allowed into the study if the dose has been stable for at least two months before the study baseline visit. * Have a history or indication of drug and/or alcohol abuse at the time of enrolment. * Have a habitual alcohol consumption of \>2 alcoholic beverages/day (\>28g ethanol daily). * Follow a vegetarian or vegan diet. * Have a typical fibre intake of \>30g per day. * Have experienced major dietary changes within three months before the study baseline. * Plan major lifestyle changes (diet, physical activity, or travel) during the study period. * Have a clinically diagnosed eating disorder. * Have a food allergy or intolerance that would preclude study product intake (for example, eggs, gluten, nuts, milk, or any other food allergy or intolerance). * Have an active gastrointestinal disorder or previous gastrointestinal surgery. * Have a significant active and medically-diagnosed acute or chronic co-existing illness including: metabolic, psychiatric, cardiovascular, endocrinological, immunological condition, gastrointestinal disease or any other condition which contraindicates, in the investigator's judgement, entry to the study (such as, diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers, hepatitis A/B/C, HIV, cancer, diabetes etc) or a significant history of such diseases. * Are severely immunocompromised (e.g., HIV positive, transplant patient, on anti-rejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last 12 months). * Have a malignant disease or concomitant end-stage organ disease. * Have symptomatic respiratory or cardiac illness. * Experience alarm features such as sudden weight loss, rectal bleeding, a recent change in bowel habits, or significant abdominal pain within three months before baseline. * Individuals who, in the opinion of the investigator, are poor attendees or unlikely for any reason to be able to comply with the study protocol. * Are receiving treatment involving experimental drugs. * If the participant has been in a recent experimental trial, these must have been completed not less than 30 days before this study. * Individuals who regularly undertake rigorous exercise. * Individuals who smoke or vape.
Conditions Diabetes Type 2, Type II Diabetes Mellit...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to adapt, implement, and evaluate PLA based intervention in Rural Kabul, Afghanistan for TIIDM prevention and control.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: PLA — An PLA based intervention would be carried out to prepare the individuals with TIIDM. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the community. The study participants would be evaluated after completion of 10 months of the intervention. A structured, validated and literature-based end line assessment checklist will be devised to assess the feasibility of the intervention.

Primary Outcomes

  • To culturally adapt PLA-based intervention (D-Magic) for primary prevention and control of TIIDM in rural communities of Afghanistan (10 months)
  • To test the feasibility of the culturally adapted PLA-based intervention (D-Magic) (12 months)
  • To test the acceptability of the culturally adapted PLA-based intervention (D-Magic) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-24
Completion: 2027-09-30
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: HealthNet Transcultural Psychosocial Organization
Collaborators: University of York, Khyber Medical University Peshawar, National Institute for Health Research, United Kingdom, Aga Khan University
Principal Investigators:
  • Abdul Rahman Shahab, MPH (PRINCIPAL_INVESTIGATOR) - Deputy Country Director, HealthNet TPO, Afghanistan
Contact Information
Study Contact:
Abdul Rahman Shahab, MPH
+93786611325
abdul.shahab@hntpo.org
Sayed Murtaza Sadat Hofiani, MPH
+93700555600
rsch.coord@hntpo.org
Abdul Rahman Shahab, MPH
+93786611325
abdul.shahab@hntpo.org
HealthNet TPO, Afghanistan
Interventions
  • Behavioral: PLA — An PLA based intervention would be carried out to prepare the individuals with TIIDM. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the community. The study participants would be evaluated after completion of 10 months of the intervention. A structured, validated and literature-based end line assessment checklist will be devised to assess the feasibility of the intervention.
Study Locations (1 sites)
HealthNet TPO, Afghanistan, Kabul, Kabul 24000 Afghanistan
Eligibility Criteria
Inclusion Criteria: * For intervention phase: Individuals aged 20 years and above. For baseline and endline assessments (before and after the intervention): Individuals aged 30 years and above. * Participants residing in the randomized clusters of Kabul, Afghanistan Individuals willing to participate in the study and provide consent. * All individuals with normoglycemia, intermediate hyperglycaemia, and diabetes are encouraged to participate. * Participants who can attend the scheduled meetings and interventions as per the study protocol. Exclusion Criteria: * For Intervention phase: Individuals below the age of 20 years. For baseline and endline assessments (before and after the intervention): individuals below the age of 30 years. * Individuals unwilling to provide consent for participation. * Participants with reported health conditions that may hinder their active involvement in the study. * Individuals with non-compliance with research protocols
Conditions Type 2 Diabetes Mellitus (T2D)
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot intervention study is to learn if culturally appropriate food bundles and nutrition education can help people with diabetes who struggle to afford healthy food in patients with diabetes receiving care at Community Care Clinic in Winston-Salem, NC. The main questions we hope to answer are: 1. Can providing culturally appropriate foods and recipes improve how people cook and prepare meals at home? 2. Can this approach improve people's nutrition knowledge and help them better manage their diabetes? 3. Can this approach improve overall health outcomes for people with diabetes who face food insecurity? Participants will: 1. Complete an initial interview and survey about their food security, health challenges, and social needs 2. Receive culturally appropriate food bundles designed for their community 3. Receive easy-to-use educational materials including recipes and cooking guides that match their reading level 4. Complete follow-up surveys at 3 months and 6 months to track any changes in their cooking habits, nutrition knowledge, diabetes management, and health

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Food Bundle Intervention — Culturally tailored food bundles containing Hispanic-friendly ingredients that support diabetes management, as well as recipe resources and cooking guides designed for various literacy levels.

Primary Outcomes

  • Hemoglobin A1c (Baseline)
  • Hemoglobin A1c (Month 3)
  • Hemoglobin A1c (Month 6)
  • Self-efficacy in diabetes management (Baseline)
  • Self-efficacy in diabetes management (Month 3)
  • Self-efficacy in diabetes management (Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Principal Investigators:
  • Megan B Irby, PhD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Megan B Irby, PhD
336.758.4642
irbym@wfu.edu
Megan B Irby, PhD
Wake Forest University Health Sciences
Interventions
  • Other: Food Bundle Intervention — Culturally tailored food bundles containing Hispanic-friendly ingredients that support diabetes management, as well as recipe resources and cooking guides designed for various literacy levels.
Study Locations (1 sites)
Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years at the time of the first clinic visit during the study period; regardless of sex, gender, race, or ethnicity * Active patients of the Community Care Clinic (CCC) who received at least one clinical encounter between January 1, 2024 and December 31, 2024; with at least one scheduled follow-up appointment during the prospective study period * Meet CCC's standard eligibility criteria: Uninsured status (no health insurance coverage); Family income ≤250% of the Federal Poverty Level; Resident of Forsyth County, North Carolina, or surrounding service area * Completed at least one validated food insecurity screening tool during the study period as part of routine clinical care * Medical record contains at least one documented measurement for any of the primary outcome variables (body mass index, blood pressure, HbA1c, or healthcare utilization metric) * Documented diagnosis of Type 2 diabetes (ICD-10: E11.x) OR; Pre-diabetes diagnosis (ICD-10: R73.03) with a hemoglobin A1c ≥9.5% * Reside within designated pickup/delivery zones for food bundle distribution (primary zip codes: 27101, 27105, 27107, and adjacent service areas) * Able and willing to provide written informed consent (available in English and Spanish) * Able to participate in baseline and follow-up assessments either in English or Spanish (the two primary languages at CCC) Exclusion Criteria: * Unable to speak proficiently in English or Spanish, as this study and the CCC staff are equipped only to provide services in English and Spanish languages. * Have known food allergies (documented in the electronic medical record and/or self-reported to CCC or study staff) that may preclude participation in the food bundle program inherent to this protocol. * Have incomplete records. Medical charts with missing or incomplete demographic information (age, gender) that cannot be verified through other sources * Patients who were pregnant at any point during the study period (due to expected physiological changes in weight, blood pressure, and glucose metabolism that would confound outcome measurements) * Patients with documented terminal illness or hospice care during the study period, as their health trajectory and care priorities differ fundamentally from the general population * Transient patients. Patients who received only one-time urgent/emergent care without established continuity of care at CCC (defined as \<2 visits during study period) * Type 1 diabetes (ICD-10: E10.x) - requires different dietary management; End-stage renal disease requiring dialysis (special dietary restrictions); Active eating disorder diagnosis; Severe food allergies that would limit ability to safely consume food bundle contents; Recent bariatric surgery (\<12 months) * Documented cognitive impairment or intellectual disability that would impair ability to provide informed consent or participate meaningfully in intervention without caregiver support * Currently enrolled in other intensive nutrition intervention studies or food prescription programs that would confound assessment of the intervention's independent effects * Primary language other than English or Spanish * Plans to move outside of CCC's service area or discontinue care at CCC within the 6-month study period * Physical disabilities, literacy barriers, or other factors that would prevent completion of baseline or follow-up survey instruments, unless accommodations can be reasonably made
Conditions Type 2 Diabetes Mellitus, Prediabetes (I...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims at assessing whether consumption of olive pomace oil in the diet may benefit persons with type 2 diabetes mellitus or persons at risk of developing the disease (prediabetic persons). The main questions the study aims to answer are: * May olive pomace oil prevent a high increase of blood glucose levels when consumed in a meal together with carbohydrates in diabetic/prediabetic patients? * May olive pomace oil decrease fasting blood glucose levels of diabetic/prediabetic patients after consuming it daily? * May daily consumption of olive pomace oil improve glucose homeostasis and other alterations like elevated blood lipids or inflammation, which also affect persons with diabetes or prediabetes? Researchers will compare the effect of consuming olive pomace oil to the effects of a comparison oil (high-oleic acid sunflower oil). Participants will: In different days, they will consume white bread alone or the oils (olive pomace oil, high-oleic acid sunflower oil or extra virgin olive oil) spread on white bread and blood will be collected at different times during 2 h. This study to observe the increase of blood glucose after a carbohydrate-rich breakfast will be part of the so-called "postprandial" study, and will be conducted during 3 weeks, during which participants will consume corn oil on a daily basis. Participants will also take part in the "chronic" study, that will last 22 weeks in total. During this study, they will firstly "wash" the effects of the oil they normally consume in their diets by consuming corn oil during 3 weeks. It is during these weeks when they will attend the Human Nutrition Unit (HNU) of ICTAN to carry on the "postprandial" study described in the previous paragraph. After the initial 3 weeks, participants will consume olive pomace oil as the only oil in their diets during 8 weeks, "wash" its effects again by consuming corn oil during 3 weeks and then change to consume the other oil (high-oleic acid sunflower oil) during 8 weeks. During the chronic study, they will visit the clinic once every 4 weeks for checkups and tests. They will refrain from eating other oils or specific fat-rich foods. Participants will also attend our phone calls to ask them what they ate the day before on different weeks during the study, and wear an accelerometer during 1 week to record their physical activity. They will keep a diary of the doses of insulin/metformin used and the blood glucose levels they measured at home.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Experimental arm: Olive pomace oil — Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
  • Dietary Supplement: High-oleic acid sunflower oil — Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.

Primary Outcomes

  • Fasting blood glucose (From enrollment to the end of each treatment at 8 weeks)
  • Postprandial blood glucose response (From enrollment until week 14 of the study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-15
Completion: 2026-06-30
Eligibility
Age: 20 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Collaborators: ICTAN-CSIC - Madrid - Spain
Principal Investigators:
  • Laura Bravo, Professor (PRINCIPAL_INVESTIGATOR) - ICTAN-CSIC
Contact Information
Study Contact:
Laura Bravo, Professor
+34 91 5492300
lbravo@ictan.csic.es
Beatriz Sarria, Dr
+34 91 5492300
beasarria@ictan.csic.es
Laura Bravo, Professor
+34 91 5492300
lbravo@ictan.csic.es
Institute of Food Science, Technology and Nutrition (ICTAN-CSIC)
Interventions
  • Dietary Supplement: Experimental arm: Olive pomace oil — Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
  • Dietary Supplement: High-oleic acid sunflower oil — Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
Study Locations (1 sites)
Institute of Food Science, Technology and Nutrition (ICTAN-CSIC), Madrid, Madrid 28040 Spain
Eligibility Criteria
Inclusion Criteria: * Fasting blood glucose between 100-126 mg/dL and/or * Glycated haemoglobin (HbA1c) between 5.7-6.4% and/or * Diabetic persons with Fasting blood glucose \>126 mg/dL and/or * Diabetic persons with Glycated haemoglobin (HbA1c) \> 6.4% Exclusion Criteria: * Kidney or liver diseases * Gastrointestinal diseases (irritable bowel syndrome, Crohn disease, chronic bowel inflammation) * Food allergies/intolerances * Vegetarians/vegans * Smoking * Pregnant or lactating women * On prescription drugs other than for hypertension/thyroid/dyslipidemia/glucose control, or changes in dosage in the last 3 months * Consumption of vitamins, dietary supplements or nutraceuticals

Tezspire Cardiac Events PASS

NCT06951867
Recruiting
Conditions Cardiovascular Events, MACE
Phase Not Applicable
Enrollment 16640
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Tezepelumab — The exposure of primary interest is tezepelumab for severe asthma. Exposure will be assessed based on prescriptions or administrations depending on the data source. A comparable cohort of unexposed patients treated with high-intensity SOC will be identified based on the presence of a trigger exposure (i.e., augmentation or change of the non-biologic high-intensity treatment that does not represent treatment de-escalation) to mirror tezepelumab start in the exposed cohort. Due to the limited knowledge of the cardiovascular profile of biologics, SOC for comparative analyses will only include non-biologic high-intensity treatment.

Primary Outcomes

  • composite outcome MACE (five years from tezepelumab market launch)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-15
Completion: 2029-05-31
Eligibility
Age: 12 Years – 130 Years
Sex: ALL
Volunteers: false
Enrollment: 16640 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Collaborators: IQVIA Pvt. Ltd
Principal Investigators:
  • Peter Egger (PRINCIPAL_INVESTIGATOR) - IQVIA Pty Ltd
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
kontakt@sundhedsdata.dk
Danish registries (access/analysis)
regis.lassalle@health-data-hub.fr
French National Health Data System (SNDS)
Interventions
  • Drug: Tezepelumab — The exposure of primary interest is tezepelumab for severe asthma. Exposure will be assessed based on prescriptions or administrations depending on the data source. A comparable cohort of unexposed patients treated with high-intensity SOC will be identified based on the presence of a trigger exposure (i.e., augmentation or change of the non-biologic high-intensity treatment that does not represent treatment de-escalation) to mirror tezepelumab start in the exposed cohort. Due to the limited knowledge of the cardiovascular profile of biologics, SOC for comparative analyses will only include non-biologic high-intensity treatment.
Study Locations (4 sites)
Healthcare Integrated Research Database (HIRD), Wilmington, Delaware 19801 United States
Danish registries (access/analysis), Copenhagen, Denmark
French National Health Data System (SNDS), Paris, France
Team Gesundheit GKV Claims data (SHI), Berlin, Germany
Eligibility Criteria
Inclusion Criteria: * patients with a diagnosis of asthma receiving tezepelumab or high-intensity SOC treatment for severe asthma at any point during the study inclusion period. Exclusion Criteria for both exposed and unexposed groups include: * \<12 months of data availability prior to index date, * age \<12 years at index date, * history of congenital heart disease or heart transplant outcome-specific exclusion criterion applied for each objective will include the presence of non-fatal myocardial infarction or stroke and the specific outcome of interest in the 180 days prior to index date * for comparative analysis, an additional exclusion criterion will be considered, i.e. exposure to non-tezepelumab biologics on index date or within the 5-half-life clearance period of the biologic * matching criteria (including, among other variables, the type and duration of SOC exposure in the 12 months before index date and propensity score \[PS\] matching) will be applied to ensure exposed and unexposed patients' comparability